Apollo Stock Analysis

APEN -  USA Stock  

USD 5.55  0.05  0.89%

The big decline in price over the last few months for Apollo Endosurgery could raise concerns from institutional investors as the firm it trading at a share price of 5.55 on 420,034 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Apollo Endosurgery or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.28. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Apollo Endosurgery partners.
Please continue to Trending Equities.

Apollo Stock Analysis 

 
Refresh
The Apollo Endosurgery stock analysis report makes it easy to digest most publicly released information about Apollo Endosurgery and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Apollo Stock analysis module also helps to analyze the Apollo Endosurgery price relationship with some important fundamental indicators such as market cap and management efficiency.

Apollo Stock Analysis Notes

About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.66. Apollo Endosurgery had not issued any dividends in recent years. The entity had a split on the 30th of December 2016. Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas. Apollo Endosurgery operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 158 people. For more info on Apollo Endosurgery please contact Todd Newton at 512 279 5100 or go to https://www.apolloendo.com.

Apollo Endosurgery Quarterly Cost of Revenue

7.12 MillionShare

Apollo Endosurgery Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Apollo Endosurgery's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Apollo Endosurgery or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Apollo Endosurgery generated a negative expected return over the last 90 days
Apollo Endosurgery has high historical volatility and very poor performance
Apollo Endosurgery has a very high chance of going through financial distress in the upcoming years
Apollo Endosurgery was previously known as Apollo Endosurgery and was traded on NASDAQ Exchange under the symbol LPTN.
The company reported the previous year's revenue of 59.68 M. Net Loss for the year was (17.78 M) with profit before overhead, payroll, taxes, and interest of 22.24 M.
Apollo Endosurgery currently holds about 27.35 M in cash with (12.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69.
Apollo Endosurgery has a poor financial position based on the latest SEC disclosures
Roughly 56.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Apollo Endosurgery Inc Shares Close the Week 22.6 percent Lower - Weekly Wrap - Nasdaq

Apollo Endosurgery Upcoming and Recent Events

Earnings reports are used by Apollo Endosurgery to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apollo Endosurgery previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Earnings Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Apollo Largest EPS Surprises

Earnings surprises can significantly impact Apollo Endosurgery's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-03-26
2019-12-31-0.38-0.340.0410 
2021-11-01
2021-09-30-0.28-0.230.0517 
2021-05-04
2021-03-31-0.22-0.170.0522 
View All Earnings Estimates

Apollo Endosurgery SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Apollo Endosurgery prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Apollo Endosurgery investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Apollo Endosurgery specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of December 2021
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
20th of December 2021
Unclassified Corporate Event
View
1st of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
19th of October 2021
Unclassified Corporate Event
View
14th of October 2021
Financial Statements and Exhibits. Other Events
View
12th of October 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
7th of October 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Apollo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Apollo Endosurgery is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apollo Endosurgery backward and forwards among themselves. Apollo Endosurgery's institutional investor refers to the entity that pools money to purchase Apollo Endosurgery's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Cpmg IncCommon Shares3.2 M28.9 M
Nantahala Capital Management LlcCommon Shares2.5 M22.8 M
Gagnon Securities LlcCommon Shares1.5 M14 M
Gagnon Advisors LlcCommon Shares1.3 M12 M
Stonepine Capital Management LlcCommon Shares912.1 K8.3 M
Parkman Healthcare Partners LlcCommon Shares831.2 K7.5 M
Parian Global Management LpCommon Shares820.4 K7.4 M
Note, although Apollo Endosurgery's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Apollo Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 233.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apollo Endosurgery's market, we take the total number of its shares issued and multiply it by Apollo Endosurgery's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Apollo Profitablity

Apollo Endosurgery's profitability indicators refer to fundamental financial ratios that showcase Apollo Endosurgery's ability to generate income relative to its revenue or operating costs. If, let's say, Apollo Endosurgery is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Apollo Endosurgery's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Apollo Endosurgery's profitability requires more research than a typical breakdown of Apollo Endosurgery's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (29.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (28.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.28.
Last ReportedProjected for 2022
Return on Average Assets(0.29) (0.31) 
Return on Average Equity(71.53) (73.41) 
Return on Invested Capital(0.26) (0.27) 
Return on Sales(0.47) (0.51) 

Management Efficiency

The entity has return on total asset (ROA) of (13.79) % which means that it has lost $13.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (344.38) %, meaning that it created substantial loss on money invested by shareholders. Apollo Endosurgery management efficiency ratios could be used to measure how well apollo endosurgery manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.31. The value of Return on Average Equity is estimated to slide to -73.41. Apollo Endosurgery Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 25.66 Million. Goodwill and Intangible Assets is expected to rise to about 17.8 M this year, although the value of Total Assets will most likely fall to about 83 M.
Last ReportedProjected for 2022
Book Value per Share 0.27  0.29 
Enterprise Value over EBIT(6.90) (7.44) 
Enterprise Value over EBITDA(9.09) (9.81) 
Price to Book Value 11.69  13.43 
Tangible Assets Book Value per Share 2.62  2.68 
Enterprise Value122.6 M132.3 M
Tangible Asset Value76 M65.2 M

Technical Drivers

As of the 21st of January, Apollo Endosurgery shows the mean deviation of 2.57, and Risk Adjusted Performance of (0.12). Apollo Endosurgery technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Apollo Endosurgery, which can be compared to its rivals. Please confirm Apollo Endosurgery jensen alpha, as well as the relationship between the potential upside and skewness to decide if Apollo Endosurgery is priced correctly, providing market reflects its regular price of 5.55 per share. Given that Apollo Endosurgery has jensen alpha of (0.53), we suggest you to validate Apollo Endosurgery's prevailing market performance to make sure the company can sustain itself at a future point.

Apollo Endosurgery Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Apollo Endosurgery price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Apollo Endosurgery Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apollo Endosurgery insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apollo Endosurgery's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apollo Endosurgery insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Apollo Endosurgery Predictive Daily Indicators

Apollo Endosurgery intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apollo Endosurgery stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Apollo Endosurgery Forecast Models

Apollo Endosurgery time-series forecasting models is one of many Apollo Endosurgery's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apollo Endosurgery's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Apollo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apollo Endosurgery stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apollo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Apollo Endosurgery. By using and applying Apollo Stock analysis, traders can create a robust methodology for identifying Apollo entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.37) (0.40) 
Gross Margin 0.48  0.57 
Profit Margin(0.62) (0.67) 
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas. Apollo Endosurgery operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 158 people.

Current Apollo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apollo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apollo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.8Strong Buy5Odds
Apollo Endosurgery current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Apollo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apollo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apollo Endosurgery, talking to its executives and customers, or listening to Apollo conference calls.
Apollo Analyst Advice Details

Apollo Stock Analysis Indicators

Apollo Endosurgery stock analysis indicators help investors evaluate how Apollo Endosurgery stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apollo Endosurgery shares will generate the highest return on investment. By understating and applying Apollo Endosurgery stock analysis, traders can identify Apollo Endosurgery position entry and exit signals to maximize returns.
Quick Ratio2.53
Fifty Two Week Low3.80
Revenue Growth27.50%
Shares Short Prior Month301.47k
Average Daily Volume Last 10 Day315.52k
Average Daily Volume In Three Month278.84k
Shares Percent Shares Out1.54%
Gross Margins55.38%
Short Percent Of Float1.97%
Forward Price Earnings-7.30
Float Shares30.39M
Fifty Two Week High10.39
Enterprise Value To Ebitda-26.93
Fifty Day Average8.29
Two Hundred Day Average8.05
Enterprise Value To Revenue6.03
Please continue to Trending Equities. Note that the Apollo Endosurgery information on this page should be used as a complementary analysis to other Apollo Endosurgery's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Apollo Stock analysis

When running Apollo Endosurgery price analysis, check to measure Apollo Endosurgery's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apollo Endosurgery is operating at the current time. Most of Apollo Endosurgery's value examination focuses on studying past and present price action to predict the probability of Apollo Endosurgery's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apollo Endosurgery's price. Additionally, you may evaluate how the addition of Apollo Endosurgery to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Apollo Endosurgery's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollo Endosurgery. If investors know Apollo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollo Endosurgery listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Apollo Endosurgery is measured differently than its book value, which is the value of Apollo that is recorded on the company's balance sheet. Investors also form their own opinion of Apollo Endosurgery's value that differs from its market value or its book value, called intrinsic value, which is Apollo Endosurgery's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollo Endosurgery's market value can be influenced by many factors that don't directly affect Apollo Endosurgery's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollo Endosurgery's value and its price as these two are different measures arrived at by different means. Investors typically determine Apollo Endosurgery value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollo Endosurgery's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.